comparemela.com

Latest Breaking News On - Brings total seriesb funds raised - Page 1 : comparemela.com

Grey Wolf Therapeutics Closes Oversubscribed $50 Million Series B Financing Expansion, Led by ICG Life Sciences Team, to Accelerate and Expand First-of-its-Kind Antigen Modulation Technology

/PRNewswire/ Grey Wolf Therapeutics ("Grey Wolf" or "the company"), a clinical-stage biotechnology company leveraging first-of-its-kind antigen modulation.

United statesCity ofUnited kingdomCatherine armstrongPeter joyceTim bronsTracy weightmanOxford science enterprisesHead of corporate communicationsAmerican society of clinical oncologyLondon stock exchangeLife sciencesBrings total seriesb funds raisedSupport broadening scopeOngoing clinical trialFirst clinical data

Grey Wolf Therapeutics Closes Oversubscribed $50 Million Series B Financing Expansion, Led by ICG Life Sciences, to Accelerate and Expand First-of-its-Kind Antigen Modulation Technology

Grey Wolf Therapeutics Closes Oversubscribed $50 Million Series B Financing Expansion, Led by ICG Life Sciences, to Accelerate and Expand First-of-its-Kind Antigen Modulation Technology

United kingdomUnited statesPeter joyceTracy weightmanAmerican society of clinical oncologyLife sciencesOxford science enterprisesBrings total seriesb funds raisedSupport broadening scopeOngoing clinical trialFirst clinical dataExpand rd effortsDevelop disease modifying therapiesGrey wolf therapeuticsPfizer venturesAndera partners

vimarsana © 2020. All Rights Reserved.